EPO and Alzheimer disease: Similarly, patients who received both EPO and iron supplements concomitantly also presented a reduced risk of VaD (adjusted HR = 0.39, 95% CI, 0.24–0.64) and UnD (adjusted HR = 0.50, 95% CI, 0.42–0.61), but not AD (adjusted HR = 0.48, 95% CI = 0.19–1.24).